JNJ-89495120治疗重度抑郁症疗效的研究 (Moonlight-1)
一项随机、双盲、多中心、安慰剂对照、概念验证研究,旨在评估 JNJ-89495120 作为单一疗法对患有重度抑郁症 (MDD) 的成年参与者的有效性、安全性和耐受性
The purpose of this study is to evaluate how well JNJ-89495120 works (anti-depressant effects) and how well it is tolerated as compared to placebo on reducing the symptoms of depression in participants with major depressive disorder (MDD).
研究概览
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
Alabama
-
Huntsville、Alabama、美国、35801
- UAB Huntsville Regional Medical Campus
-
-
Arizona
-
Chandler、Arizona、美国、85224
- Chandler Clinical Trials
-
Phoenix、Arizona、美国、85012
- IMA Clinical Research PC Phoenix
-
Tucson、Arizona、美国、85724
- University of Arizona
-
Tucson、Arizona、美国、85704
- Noble Clinical Research
-
-
California
-
Bellflower、California、美国、90706
- CI Trials
-
Encino、California、美国、91316
- Wake Research PRI Encino
-
Garden Grove、California、美国、92844
- National Institute Of Clinical Research
-
Newport Beach、California、美国、92660
- WR-Newport Beach
-
Orange、California、美国、92866
- ATP Clinical Research
-
Redlands、California、美国、92374
- Anderson Clinical Research
-
San Diego、California、美国、92103
- Artemis Institute for Clinical Research
-
San Jose、California、美国、95124
- Lumos Clinical Research Center LLC
-
Santa Ana、California、美国、92705
- Syrentis Clinical Research
-
Temecula、California、美国、92591
- Inland Psychiatric Medical Group Inc
-
Walnut Creek、California、美国、94596
- Sunwise Clinical Research
-
-
Colorado
-
Denver、Colorado、美国、80209
- Mountain View Clinical Research
-
-
Florida
-
Fort Myers、Florida、美国、33912
- Gulfcoast Medical Research Center
-
Hollywood、Florida、美国、33021
- The Medici Medical Research
-
Homestead、Florida、美国、33030
- Advanced Research Institute of Miami
-
Maitland、Florida、美国、32751
- K2 Medical Research
-
Miami、Florida、美国、33126
- Pharmax Research Clinic Inc
-
Miami、Florida、美国、33135
- Wellness Research Center
-
Pembroke Pines、Florida、美国、33024
- Best Choice Medical and Research Service
-
Tampa、Florida、美国、33629
- Interventional Psychiatry of Tampa Bay
-
West Palm Beach、Florida、美国、33407
- Health Synergy Clinical Research
-
-
Georgia
-
Atlanta、Georgia、美国、30328
- Synexus Clinical Research US Inc
-
Decatur、Georgia、美国、30030
- iResearch Atlanta LLC
-
Snellville、Georgia、美国、30078
- Accelerated Clinical Research Group LLC
-
-
Illinois
-
Chicago、Illinois、美国、60637
- University of Chicago Medical Center
-
-
Indiana
-
Indianapolis、Indiana、美国、46202
- Indiana University IU Health
-
-
Louisiana
-
New Orleans、Louisiana、美国、70115
- DelRicht Research
-
-
Maryland
-
Gaithersburg、Maryland、美国、20877
- CBH Health
-
-
Massachusetts
-
Worcester、Massachusetts、美国、01655
- University of Massachusetts Medical School
-
-
New York
-
Brooklyn、New York、美国、11229
- Integrative Clinical Trials LLC
-
-
Ohio
-
Cincinnati、Ohio、美国、45219
- University of Cincinnati
-
Cincinnati、Ohio、美国、45215
- Patient Priority Clinical Sites LLC
-
Columbus、Ohio、美国、43210
- OSU Department of Psychiatry and Behavioral Health
-
-
Oklahoma
-
Oklahoma City、Oklahoma、美国、73116
- Paradigm Research Professionals, LLC
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国、19104
- University of Pennsylvania
-
-
South Carolina
-
North Charleston、South Carolina、美国、29405
- Coastal Carolina Research Center
-
-
Texas
-
McKinney、Texas、美国、75071
- Revival Research Institute LLC
-
-
Utah
-
Clinton、Utah、美国、84015
- Alpine Research Organization
-
-
Washington
-
Everett、Washington、美国、98201
- Core Clinical Research
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Primary psychiatric diagnosis of recurrent major depressive disorder, without psychotic features, based on clinical assessment using diagnostic and statistical manual of mental disorders (DSM)-5 criteria and confirmed with the mini international neuropsychiatric interview (MINI)
- Participant had to have at least one previous major depressive disorder (MDD) episode prior to their current episode
- Were first diagnosed with depression before the age of 55
- Are in a current episode of depression: Episode length must be at least 2 months but not longer than 24 months
- Have taken 0, 1, or 2 treatments for depression in your current episode
- Body mass index (BMI) within the range 18 to 35 kilograms per square meter (kg/m^2) at screening
Exclusion Criteria:
- Treatment with vagus nerve stimulation (VNS), electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), deep brain stimulation (DBS), or ketamine/esketamine within the current or past major depressive episodes
- Current or past DSM-5 diagnosis of bipolar disorder, psychotic disorders, borderline personality disorder, antisocial personality disorder, or current obsessive-compulsive disorder
- Post-traumatic stress disorder within the past three years of screening
- Dementia, any dementing disease, intellectual disability, or neurocognitive disorder
- History of Alcohol and Substance use disorders within 6 months of screening, with the exclusion of nicotine, caffeine, and mild cannabis use disorder, according to the MINI and Clinical Assessment
- Known allergies, hypersensitivity, or intolerance to JNJ-89495120 or its excipients
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Arm 1: JNJ-89495120 Dose A
Participants will receive JNJ-89495120 dose A during the double-blind (DB) treatment phase in Period 1 and Period 2 of the study. |
JNJ-89495120 will be administered. |
|
实验性的:Arm 2: JNJ-89495120 Dose A and Dose B
Participants will receive JNJ-89495120 dose A in Period 1 followed by JNJ-89495120 dose B in Period 2 during the DB treatment phase of the study. |
JNJ-89495120 will be administered. |
|
安慰剂比较:Arm 3: Placebo Group
Participants will receive placebo matched to JNJ-89495120 during the DB treatment phase in Period 1 and Period 2 of the study. |
Placebo will be administered. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score to Day 5
大体时间:Baseline up to Day 5
|
The MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition. |
Baseline up to Day 5
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change from Baseline in MADRS Total Score to Day 2
大体时间:Baseline up to Day 2
|
The MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition. |
Baseline up to Day 2
|
|
Change from Baseline in Clinician Global Impression-Severity (CGI-S) Scale Score to Days 2 and 5
大体时间:Baseline up to Day 2 and Day 5
|
The CGI-S provides an overall clinician-determined summary measure of the severity of the participant's illness. The CGI-S evaluates the severity of psychopathology on a scale of 1 to 7. Participant is assessed on severity of illness at the time of rating according to: 1=normal (not at all ill); 2=borderline ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill participants. Higher score indicating greater severity. |
Baseline up to Day 2 and Day 5
|
|
Change from Baseline in Symptoms of Major Depressive Disorder Scale (SMDDS) Total Score to Day 5
大体时间:Baseline up to Day 5
|
The SMDDS is a 16-item patient reported outcome (PRO) measure. Each item is rated by the participant according to a 5-point Likert scale, where 0 denotes "Not at all" or "Never" and 4 denotes "Extremely" or "Always". Before summing the items to create a total score, item 11 and item 12 are combined into a single score by selecting the highest severity on either item. The total score is then created by summing the responses on the 15 items, which range from 0 to 60. Higher score indicates more severe depressive symptomatology. |
Baseline up to Day 5
|
|
Change from Baseline in Generalized Anxiety Disorder-7 (GAD-7) Scale Score to Day 5
大体时间:Baseline up to Day 5
|
The GAD-7 scale is a self-administered questionnaire designed to measure anxiety. GAD-7 has seven items, which measure frequency of various signs of GAD using a 4-point Likert scale (where, Not at all = 0, Several days = 1, More than half the days = 2, and Nearly every day = 3). The total score ranges from 0 to 21 with increasing scores indicative of greater severity of symptoms of anxiety. Severity of anxiety on the GAD-7 is rated as follows: none (0-4), mild (5-9), moderate (10-14) and severe (15-21). |
Baseline up to Day 5
|
|
Number of Participants with Adverse Events (AEs)
大体时间:Up to approximately 18 weeks
|
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. |
Up to approximately 18 weeks
|
|
Number of Participants with Abnormalities in Vital Signs Parameters
大体时间:Up to approximately 18 weeks
|
Participants with abnormalities in vital signs (supine blood pressure, pulse/heart rate, respiratory rate, oral temperature) parameters will be reported. |
Up to approximately 18 weeks
|
|
Number of Participants with 12-Lead Electrocardiogram (ECG) Abnormalities
大体时间:Up to approximately 18 weeks
|
Participants with 12-lead ECG abnormalities will be reported. |
Up to approximately 18 weeks
|
|
Number of Participants With Abnormalities in Laboratory Parameters
大体时间:Up to approximately 18 weeks
|
Participants with abnormalities in clinical laboratory parameters (hematology and serum chemistry) will be reported. |
Up to approximately 18 weeks
|
|
Number of Participants Reporting Changes in Weight/Body Mass Index (BMI)
大体时间:Up to approximately 18 weeks
|
Participants with changes in weight/BMI will be reported. |
Up to approximately 18 weeks
|
|
Suicidal Ideation Assessment Using Columbia Suicide Severity Rating Scale (C-SSRS) Score
大体时间:Up to approximately 18 weeks
|
The C-SSRS scale consists of 28 items in 4 sections: suicide behavior, actual attempts, suicidal ideation, and intensity of ideation. Suicidal ideation consists of 5 'yes/no' items: wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods (not plan) without intention to act, active suicidal ideation with some intent to act without specific plan, active suicidal ideation with specific plan and intent. Only items with yes responses are listed. Worsening of suicidal ideation was an increase in severity of suicidal ideation from baseline. |
Up to approximately 18 weeks
|
|
Change from Baseline in Cognitive Functioning Measured by the Hopkins Verbal Learning Test-Revised (HVLT-R)
大体时间:From Baseline up to 4 weeks
|
The HVLT-R, a measure of verbal learning and memory, is a 12-item word list recall test. Administration includes 3 learning trials, a delayed recall (20-minute) trial, and a 24-word recognition list (including 12 target and 12 foil words). The test administrator reads instructions and word lists aloud, and records words recalled/recognized by the participant. Three learning trials are combined to calculate a total recall score learning, delayed recall, and recognition trials. |
From Baseline up to 4 weeks
|
|
Change from Baseline in Cognitive Functioning Measured by the Digit Symbol Substitution Test (DSST)
大体时间:From Baseline up to 4 weeks
|
The DSST is recognized as covering all of the cognitive performance aspects: speed of processing, executive functioning, and attention. The DSST measures attention, working memory, sustained visual attention and psychomotor speed. Participants are given a table that pairs digits and symbols, and asked to decipher a code using the table, completing as many as possible in 90 seconds. |
From Baseline up to 4 weeks
|
|
Plasma Concentrations of JNJ-89495120
大体时间:Pre-dose (0 hours), and Post-dose on Days 1, 5 and 13
|
Plasma concentrations of JNJ-89495120 will be reported. |
Pre-dose (0 hours), and Post-dose on Days 1, 5 and 13
|
合作者和调查者
调查人员
- 研究主任:Janssen Research & Development, LLC Clinical Trial、Janssen Research & Development, LLC
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- 89495120MDD2001
- 89495120MDD2001 (其他标识符:Janssen Research & Development, LLC)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.